between the BES and ZES, including MACE (5.5 vs. 6.4%; p ¼0.76) and stent thrombosis (0.3 vs. 0.3%; p ¼ 0.99). The secondary endpoints also were not significantly different between BES and ZES, including target lesion failure (2.0 vs. 1.6%; p ¼ 0.53), in-segment LL (mm) at 12 months (0.09AE0.37 vs. 0.05AE0.39, p ¼0.61). OCT at 6 month revealed that mean NIH thickness (mm) of BES and ZES were 59.1AE30.3, 54.0AE25.6, respectively (p¼0.49), and uncovered stent strut percentage (%) of BES and ZES were 20. 5AE21.8, 17.7AE22.4, respectively (p¼0.63). Conclusion: BES with biodegradable polymer with 6 month DAPT did not increase the risk of MACE, stent thrombosis, target lesion failure, and LL at 12 months comparing with ZES with durable polymer. The 2nd generation DES including BES and ZES are comparably efficacious. Our results need to be confirmed in larger trials, and further follow up data.
Background: In spite of availability of drug-eluting stent (DES), clinical outcome of percutaneous coronary intervention for right coronary ostial lesion (RCAos) is still poor. So we investigated the angiographic and clinical outcome of DES implantation for True RCAos. Methods: This was a single center non-randomized retrospective study. From April 2007 to July 2012, 67 consecutive patients who underwent DES implantation for de novo RCAos were included. RCAos was defined as the lesion being within 3 mm of the ostium. We defined True RCAos as lesion contained just RCA ostium. Subjects were classified into two groups: the patients treated for True RCAos (True group, 35 patients) and for Not true RCAos (Not true group, 32 patients). Endpoint was binary restenosis at 10 months and target lesion revascularization (TLR) at 12 months. Results: True group was older than Not true group. There were no significant differences between two groups in gender, hypertension, hyperlipidemia, diabetes, and hemodialysis. Despite True group had shorter stent length and larger lesion diameter, they had a higher rate of binary restenosis at 10 months (35.5% vs. 10.0%, p<0.05) and TLR at 12 months (28.6% vs. 6.3%, p<0.05) than Not true group. Conclusion: Our data indicates that the outcome of DES implantation for True RCAos is worse than that of DES implantation for Not true RCAos.
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Five-year Clinical Outcomes of Drug Eluting Stents According to the On-label and Off-label Usage Jeong-Hwan Cho, Chan-Hee Lee, Hyun-Wook Lee, Tae-Hun Kwon, Yoon-Jung Choi, Jang-Won Son, Sang-Hee Lee, Ung Kim, Jeon-Seon Park, Dong-Gu Shin, Young-Jo Kim Yeungnam University Hospital, Daegu, Korea (Republic of)
Background: The purpose of this study was to evaluate clinical outcomes of drugeluting stent (DES) according to on versus off-label indication for 5 years. Methods: A total of 929 consecutive patients who performed percutaneous coronary intervention (PCI) with DES from April 2005 to December 2007 were enrolled. Those patients were divided into two groups according to on (n¼449) versus off-label (n¼480) indication. Off label usage of DES was indicated in patients with long stenotic lesion (>30mm), total occlusion, bifurcation, ostial lesion, left main disease, multivessel disease, saphenous vein graft and thrombus present. Clinical outcomes of major adverse cardiac event (MACE) including death, target vessel revascularization (TVR), target lesion revascularization (TLR), myocardial infarction (MI) and stent thrombosis (ST) were compared between two groups for 5 years. Risk factors for MACE according to on versus off label indication. Results: There were no difference between two groups in baseline characteristics, except diabetes (24.9% [Group 1] vs. 35.4%[Group 2], p¼0.002). Of 929 patients enrolled in this study, seven hundred ten patients were completely monitored for 5years (follow up rate 76.4%). At one year, group 2 was associated of higher incidence of MACE (1.9% vs. 7.5%, p¼0.000), because of TLR(1.4% vs. 3.4%, p¼0.047), TVR(1.6% vs. 5.2%, p¼0.004) and stent thrombosis(0.2% vs. 1.5%, p¼0.042). From 1 year until 5 year clinical follow up, group 2 also had a higher incidence of MACE(6.4% vs. 11.3%, p¼0.014) because of TLR(3.7% vs. 7.1%, p¼0.029). The rate of total MACE were higher in off-label usage than those of on-label (9.1% vs. 20.0%, p¼0.000 
